2021年2月1日 · Summary of the basic studies, patents, and clinical trials inhibiting TGF-β signalling, a critical pathway in tumorigenesis and fibrosis. Small molecular inhibitors and neutralizing antibodies against TGF-β signaling are potential strategies for cancer therapy.

This review focuses on the TGF-β signaling that contributes to tumor progression and immune evasion in the tumor microenvironment and presents recent achievements on TGF-β signaling inhibition as a single or combined therapeutic approach in cancer therapy.

2024年3月22日 · In this review, we retrace the research history of TGF-β and introduce the molecular mechanisms regarding its biosynthesis, activation, and signal transduction. We also provide deep insights...

2021年1月8日 · How TGFβ inhibitors elicit their anticancer effect in patients is frequently unclear, but its reversal of immunosuppressive activity in the TME might be of key importance.

2021年4月6日 · Based upon a wealth of preclinical studies, the TGF-β pathway has been pharmacologically targeted using small molecule inhibitors, TGF-β-directed chimeric monoclonal antibodies, ligand traps, antisense oligonucleotides and vaccines that have been now evaluated in …

2021年10月20日 · Based on this rationale, several classes of TGFβ inhibitors have been developed and tested in clinical trials, namely, monoclonal, neutralizing, and bifunctional antibodies; antisense oligonucleotides; TGFβ-related vaccines; and receptor kinase inhibitors.

Advances in understanding the role of transforming growth factor (TGF)-beta in tumorigenesis have led to the development of TGF-beta inhibitors for cancer treatment. Three platforms of TGF-beta inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and …

Even short-term dosing with TGF-β inhibitors might provide a considerable therapeutic window in potentiating radiotherapy. Moreover, RT can cause disfiguring and painful fibrosis, itself a target for anti-TGF-β therapy, possibly providing an added benefit of TGF-β …

Inhibitors for the TGF-beta superfamily have great potential for multiple clinical applications. Inhibition of either TGF-beta or activin could delay cancer progression and prevent fibro-sis. Myostatin inhibition is a promising novel thera-peutic strategy to treat muscular disorders, including muscu-lar dystrophy.

Recently, it was reported that transforming growth factor-beta (TGF-β) signaling pathway participated in cancer immune escape and ICI resistance. Concurrent TGF-β blockade might be a feasible strategy to enhance the efficacy of immunotherapy and relieve ICI resistance.